Worthington Financial Partners LLC Acquires Shares of 1,927 Medpace Holdings, Inc. $MEDP

Worthington Financial Partners LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 1,927 shares of the company’s stock, valued at approximately $1,082,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bayban bought a new position in Medpace during the 4th quarter worth approximately $44,000. Pacer Advisors Inc. raised its stake in Medpace by 38.1% during the 4th quarter. Pacer Advisors Inc. now owns 153,652 shares of the company’s stock worth $86,299,000 after buying an additional 42,362 shares during the period. Virtu Financial LLC lifted its holdings in Medpace by 83.7% during the fourth quarter. Virtu Financial LLC now owns 1,835 shares of the company’s stock worth $1,031,000 after acquiring an additional 836 shares in the last quarter. Blue Capital Inc. bought a new position in Medpace during the fourth quarter worth about $507,000. Finally, Dorsey Wright & Associates grew its stake in Medpace by 126.8% in the fourth quarter. Dorsey Wright & Associates now owns 22,420 shares of the company’s stock valued at $12,592,000 after acquiring an additional 12,535 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

Shares of MEDP opened at $460.20 on Friday. The company has a market cap of $13.14 billion, a price-to-earnings ratio of 28.93, a PEG ratio of 2.33 and a beta of 1.18. Medpace Holdings, Inc. has a 1-year low of $301.90 and a 1-year high of $628.92. The company’s fifty day simple moving average is $452.12 and its 200 day simple moving average is $499.49.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the company posted $3.67 earnings per share. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MEDP. Royal Bank Of Canada lowered their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Barclays cut their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Robert W. Baird dropped their target price on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Finally, BMO Capital Markets cut their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $467.08.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.